ticagrelor


( Last Updated : October 10, 2018)
Generic Name:
ticagrelor
Project Status:
Complete
Therapeutic Area:
Prevention of atherothrombotic events with history of myocardial infarction
Manufacturer:
AstraZeneca Canada Inc
Call for patient/clinician input open:
Brand Name:
Brilinta
Project Line:
Reimbursement Review
Project Number:
SR0474-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Submission Type:
Initial
Indications:
Prevention of atherothrombotic events with history of myocardial infarction
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation: